Immuneering (IMRX) Treasury Shares (2020 - 2021)
Immuneering's (IMRX) quarterly Treasury Shares came in at $6.0 million in Q2 2021, up 141.68% year-on-year from $2.5 million in Q2 2020, and up 66.67% quarter-over-quarter from $3.6 million in Q1 2021.
Immuneering (IMRX) Treasury Shares (2020 - 2021) Analysis & Trends
Immuneering's Treasury Shares history runs 2 years deep, the most recent figure standing at $6.0 million for Q2 2021.
- On a quarterly basis, Treasury Shares rose 141.68% year-over-year to $6.0 million in Q2 2021; TTM through Jun 2021 was $6.0 million, a 141.68% increase from a year earlier, with the FY2020 full-year figure at $3.6 million, changed N/A from the prior year.
- Treasury Shares grew to $6.0 million in Q2 2021 per IMRX's latest filing, from $3.6 million in the prior quarter.
- Across five years, Treasury Shares topped out at $6.0 million in Q2 2021 and bottomed at $2.5 million in Q2 2020.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Treasury Shares (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | -21,709.08 |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | 265,401.92 |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | - |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 34.70 Mn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | - |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | 5.14 Mn |
| 10 | Immuneering | 279.33 Mn | 279.33 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2021 | 6.03 Mn |
| Jun 30, 2021 | 6.03 Mn |
| Mar 31, 2021 | 3.62 Mn |
| Mar 31, 2021 | 3.62 Mn |
| Dec 31, 2020 | 3.62 Mn |
| Dec 31, 2020 | 3.62 Mn |
| Sep 30, 2020 | 2.50 Mn |
| Sep 30, 2020 | 2.50 Mn |
| Jun 30, 2020 | 2.50 Mn |
| Jun 30, 2020 | 2.50 Mn |